{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:12:48Z","timestamp":1785352368133,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22kk0305014"],"award-info":[{"award-number":["JP22kk0305014"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ck0106759"],"award-info":[{"award-number":["JP22ck0106759"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ck0106607"],"award-info":[{"award-number":["JP22ck0106607"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ck0106612"],"award-info":[{"award-number":["JP22ck0106612"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12185-022-03501-x","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T19:35:49Z","timestamp":1669923349000},"page":"155-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recent progress in pediatric lymphoblastic leukemia"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5145-1774","authenticated-orcid":false,"given":"Motohiro","family":"Kato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"3501_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12185-013-1364-2","volume":"98","author":"K Horibe","year":"2013","unstructured":"Horibe K, Saito AM, Takimoto T, Tsuchida M, Manabe A, Shima M, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006\u20132010): based on registry data from the Japanese society of pediatric hematology. Int J Hematol. 2013;98:74\u201388.","journal-title":"Int J Hematol"},{"key":"3501_CR2","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.20.00494","volume":"39","author":"AL Angiolillo","year":"2021","unstructured":"Angiolillo AL, Schore RJ, Kairalla JA, Devidas M, Rabin KR, Zweidler-McKay P, et al. Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: results from children\u2019s oncology group AALL0932. J Clin Oncol. 2021;39:1437\u201347.","journal-title":"J Clin Oncol"},{"key":"3501_CR3","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1200\/JCO.19.02892","volume":"38","author":"WL Salzer","year":"2020","unstructured":"Salzer WL, Burke MJ, Devidas M, Dai Y, Hardy KK, Kairalla JA, et al. Impact of intrathecal triple therapy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: children\u2019s oncology group study AALL1131. J Clin Oncol. 2020;38:2628\u201338.","journal-title":"J Clin Oncol"},{"key":"3501_CR4","doi-asserted-by":"publisher","first-page":"986","DOI":"10.3324\/haematol.2018.204545","volume":"104","author":"MJ Burke","year":"2019","unstructured":"Burke MJ, Salzer WL, Devidas M, Dai Y, Gore L, Hilden JM, et al. Replacing cyclophosphamide\/cytarabine\/mercaptopurine with cyclophosphamide\/etoposide during consolidation\/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica. 2019;104:986\u201392.","journal-title":"Haematologica"},{"key":"3501_CR5","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1200\/JCO.20.00256","volume":"38","author":"KP Dunsmore","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M, Wood BL, Esiashvili N, Chen Z, et al. Children\u2019s oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol. 2020;38:3282\u201393.","journal-title":"J Clin Oncol"},{"key":"3501_CR6","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.19.01692","volume":"37","author":"S Jeha","year":"2019","unstructured":"Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16. J Clin Oncol. 2019;37:3377\u201391.","journal-title":"J Clin Oncol"},{"key":"3501_CR7","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1200\/JCO.20.03692","volume":"39","author":"LM Vrooman","year":"2021","unstructured":"Vrooman LM, Blonquist TM, Stevenson KE, Supko JG, Hunt SK, Cronholm SM, et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11\u2013001. J Clin Oncol. 2021;39:3496\u2013505.","journal-title":"J Clin Oncol"},{"key":"3501_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28719","volume":"68","author":"MA Burns","year":"2021","unstructured":"Burns MA, Place AE, Stevenson KE, Gutierrez A, Forrest S, Pikman Y, et al. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: results from DFCI ALL consortium protocols 05\u2013001 and 11\u2013001. Pediatr Blood Cancer. 2021;68: e28719.","journal-title":"Pediatr Blood Cancer"},{"key":"3501_CR9","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","volume":"115","author":"V Conter","year":"2010","unstructured":"Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115:3206\u201314.","journal-title":"Blood"},{"key":"3501_CR10","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","volume":"118","author":"M Schrappe","year":"2011","unstructured":"Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grumayer R, Moricke A, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood. 2011;118:2077\u201384.","journal-title":"Blood"},{"key":"3501_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/leu.2017.265","volume":"32","author":"N Toft","year":"2018","unstructured":"Toft N, Birgens H, Abrahamsson J, Griskevicius L, Hallbook H, Heyman M, et al. Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia. Leukemia. 2018;32:606\u201315.","journal-title":"Leukemia"},{"key":"3501_CR12","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1200\/JCO.2011.40.5936","volume":"30","author":"AE Yeoh","year":"2012","unstructured":"Yeoh AE, Ariffin H, Chai EL, Kwok CS, Chan YH, Ponnudurai K, et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol. 2012;30:2384\u201392.","journal-title":"J Clin Oncol"},{"key":"3501_CR13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41588-018-0315-5","volume":"51","author":"Z Gu","year":"2019","unstructured":"Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51:296\u2013307.","journal-title":"Nat Genet"},{"key":"3501_CR14","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1182\/blood.2022015444","volume":"139","author":"S Kimura","year":"2022","unstructured":"Kimura S, Montefiori L, Iacobucci I, Zhao Y, Gao Q, Paietta EM, et al. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. Blood. 2022;139:3519\u201331.","journal-title":"Blood"},{"key":"3501_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","volume":"10","author":"ML Den Boer","year":"2009","unstructured":"Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10:125\u201334.","journal-title":"Lancet Oncol"},{"key":"3501_CR16","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/S2352-3026(20)30353-7","volume":"8","author":"ML den Boer","year":"2021","unstructured":"den Boer ML, Cario G, Moorman AV, Boer JM, de Groot-Kruseman HA, Fiocco M, et al. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematol. 2021;8:e55\u201366.","journal-title":"Lancet Haematol"},{"key":"3501_CR17","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","volume":"32","author":"KG Roberts","year":"2014","unstructured":"Roberts KG, Pei D, Campana D, Payne-Turner D, Li Y, Cheng C, et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014;32:3012\u201320.","journal-title":"J Clin Oncol"},{"key":"3501_CR18","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/jamaoncol.2021.6826","volume":"8","author":"SHR Lee","year":"2022","unstructured":"Lee SHR, Antillon-Klussmann F, Pei D, Yang W, Roberts KG, Li Z, et al. Association of genetic ancestry with the molecular subtypes and prognosis of childhood acute lymphoblastic leukemia. JAMA Oncol. 2022;8:354\u201363.","journal-title":"JAMA Oncol"},{"key":"3501_CR19","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.beha.2017.07.003","volume":"30","author":"KG Roberts","year":"2017","unstructured":"Roberts KG. The biology of Philadelphia chromosome-like ALL. Best Pract Res Clin Haematol. 2017;30:212\u201321.","journal-title":"Best Pract Res Clin Haematol"},{"key":"3501_CR20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1182\/bloodadvances.2019000163","volume":"4","author":"RC Harvey","year":"2020","unstructured":"Harvey RC, Tasian SK. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia. Blood Adv. 2020;4:218\u201328.","journal-title":"Blood Adv"},{"key":"3501_CR21","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1111\/cas.15427","volume":"113","author":"S Fukuhara","year":"2022","unstructured":"Fukuhara S, Oshikawa-Kumade Y, Kogure Y, Shingaki S, Kariyazono H, Kikukawa Y, et al. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Sci. 2022;113:2763\u201377.","journal-title":"Cancer Sci"},{"key":"3501_CR22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","volume":"2","author":"Y Gocho","year":"2021","unstructured":"Gocho Y, Liu J, Hu J, Yang W, Dharia NV, Zhang J, et al. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. Nat Cancer. 2021;2:284\u201399.","journal-title":"Nat Cancer"},{"key":"3501_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2017.75.5215","volume":"36","author":"M Qian","year":"2018","unstructured":"Qian M, Cao X, Devidas M, Yang W, Cheng C, Dai Y, et al. TP53 germline variations influence the predisposition and prognosis of B-cell acute lymphoblastic leukemia in children. J Clin Oncol. 2018;36:591\u20139.","journal-title":"J Clin Oncol"},{"key":"3501_CR24","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","volume":"373","author":"J Zhang","year":"2015","unstructured":"Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. New Engl J Med. 2015;373:2336\u201346.","journal-title":"New Engl J Med"},{"key":"3501_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/ng.3508","volume":"48","author":"T Moriyama","year":"2016","unstructured":"Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48:367\u201373.","journal-title":"Nat Genet"},{"key":"3501_CR26","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.3324\/haematol.2020.266320","volume":"106","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Yeoh AEJ, Moriyama T, Li CK, Kudo K, Arakawa Y, et al. An international retrospective study for tolerability of 6-mercaptopurine on NUDT15 bi-allelic variants in children with acute lymphoblastic leukemia. Haematologica. 2021;106:2026\u20139.","journal-title":"Haematologica"},{"key":"3501_CR27","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1182\/bloodadvances.2021005507","volume":"5","author":"M Yoshida","year":"2021","unstructured":"Yoshida M, Nakabayashi K, Yang W, Sato-Otsubo A, Tsujimoto SI, Ogata-Kawata H, et al. NUDT15 variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia. Blood Adv. 2021;5:5420\u20138.","journal-title":"Blood Adv"},{"key":"3501_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/2643-3230.BCD-20-0229","volume":"2","author":"S Jeha","year":"2021","unstructured":"Jeha S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2021;2:326\u201337.","journal-title":"Blood Cancer Discov"},{"key":"3501_CR29","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-13-3231","volume":"20","author":"D Wu","year":"2014","unstructured":"Wu D, Emerson RO, Sherwood A, Loh ML, Angiolillo A, Howie B, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res. 2014;20:4540\u20138.","journal-title":"Clin Cancer Res"},{"key":"3501_CR30","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/blood-2017-09-806521","volume":"131","author":"B Wood","year":"2018","unstructured":"Wood B, Wu D, Crossley B, Dai Y, Williamson D, Gawad C, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018;131:1350\u20139.","journal-title":"Blood"},{"key":"3501_CR31","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/S1470-2045(21)00328-4","volume":"22","author":"W Yang","year":"2021","unstructured":"Yang W, Cai J, Shen S, Gao J, Yu J, Hu S, et al. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2021;22:1322\u201332.","journal-title":"Lancet Oncol"},{"key":"3501_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/leu.2009.257","volume":"24","author":"A Moricke","year":"2010","unstructured":"Moricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010;24:265\u201384.","journal-title":"Leukemia"},{"key":"3501_CR33","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1200\/JCO.2000.18.7.1508","volume":"18","author":"Y Toyoda","year":"2000","unstructured":"Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol. 2000;18:1508\u201316.","journal-title":"J Clin Oncol"},{"key":"3501_CR34","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/leu.2016.274","volume":"31","author":"M Kato","year":"2017","unstructured":"Kato M, Ishimaru S, Seki M, Yoshida K, Shiraishi Y, Chiba K, et al. Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children. Leukemia. 2017;31:580\u20134.","journal-title":"Leukemia"},{"key":"3501_CR35","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/cncr.31099","volume":"124","author":"WL Salzer","year":"2018","unstructured":"Salzer WL, Burke MJ, Devidas M, Chen S, Gore L, Larsen EC, et al. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: a report from the children\u2019s oncology group study AALL1131. Cancer. 2018;124:1150\u20139.","journal-title":"Cancer"},{"key":"3501_CR36","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1200\/JCO.20.00493","volume":"38","author":"SB Dixon","year":"2020","unstructured":"Dixon SB, Chen Y, Yasui Y, Pui CH, Hunger SP, Silverman LB, et al. Reduced morbidity and mortality in survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. J Clin Oncol. 2020;38:3418\u201329.","journal-title":"J Clin Oncol"},{"key":"3501_CR37","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","volume":"39","author":"C Peters","year":"2021","unstructured":"Peters C, Dalle JH, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al. Total body irradiation or chemotherapy conditioning in childhood all: a multinational, randomized, noninferiority phase III study. J Clin Oncol. 2021;39:295\u2013307.","journal-title":"J Clin Oncol"},{"key":"3501_CR38","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1001\/jama.2021.0669","volume":"325","author":"PA Brown","year":"2021","unstructured":"Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:833\u201342.","journal-title":"JAMA"},{"key":"3501_CR39","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2021.0987","volume":"325","author":"F Locatelli","year":"2021","unstructured":"Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-Cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843\u201354.","journal-title":"JAMA"},{"key":"3501_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.seminhematol.2020.11.001","volume":"57","author":"E Curran","year":"2020","unstructured":"Curran E, O\u2019Brien M. Role of blinatumomab, inotuzumab, and CAR T-cells: which to choose and how to sequence for patients with relapsed disease. Semin Hematol. 2020;57:157\u201363.","journal-title":"Semin Hematol"},{"key":"3501_CR41","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S1470-2045(11)70386-2","volume":"13","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13:403\u201311.","journal-title":"Lancet Oncol"},{"key":"3501_CR42","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","volume":"4","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 2018;4:230\u20134.","journal-title":"JAMA Oncol"},{"key":"3501_CR43","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.21.01693","volume":"40","author":"MM O'Brien","year":"2022","unstructured":"O\u2019Brien MM, Ji L, Shah NN, Rheingold SR, Bhojwani D, Yuan CM, et al. Phase II trial of inotuzumab ozogamicin in children and adolescents with relapsed or refractory b-cell acute lymphoblastic leukemia: children\u2019s oncology group protocol AALL1621. J Clin Oncol. 2022;40:956\u201367.","journal-title":"J Clin Oncol"},{"key":"3501_CR44","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New Engl J Med. 2018;378:439\u201348.","journal-title":"New Engl J Med"},{"key":"3501_CR45","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/s41375-022-01550-z","volume":"36","author":"TW Laetsch","year":"2022","unstructured":"Laetsch TW, Maude SL, Balduzzi A, Rives S, Bittencourt H, Boyer MW, et al. Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed\/refractory acute lymphoblastic leukemia. Leukemia. 2022;36:1508\u201315.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03501-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-022-03501-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-022-03501-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T09:54:32Z","timestamp":1675331672000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-022-03501-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["3501"],"URL":"https:\/\/doi.org\/10.1007\/s12185-022-03501-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MK received honoraria from Amgen, Novartis, and Chugai and research funding from Otsuka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}